"A few facts"? From a medical doctor-journalist ?
Post# of 148290
(Total Views: 954)
Posted On: 08/24/2020 8:49:56 AM
Re: FIREwithCYDY #51875
"A few facts"? From a medical doctor-journalist ?
Did you do your DD on LL recently . Let me help you. On Aug 17 Cytodyn submitted its Top-line report from its phase 2 COVID-19 to the FDA and requested Emergency Use Approval.
But Ms. Saphier appears to be blissfully unaware of such a trivial event as a request for EUA. I guess she was too busy to consult a "lesser known" company's list of press releases. Instead, what a potential investor or a relative of a gravely ill Covid patient learns from her piece is that one day LL may be of use but not in the foreseeable future since it had passed only Phase 1 trial. I quote:
<<Albeit a small sample size, early Phase 1 results showed patients on Leronlimab experienced 63% less seriously adverse events than the control group, while also demonstrating reduction in viral load to zero after 14 days.>>
No comparison with the life-saving plasma therapy, right? So what is our near-term future after Phase 1? According to Ms. Saphier, we are <<currently enrolling two placebo-controlled double-blind clinical trials that have already entered Phase 3. Phase 2 results reported in July passed all safety checks.>>
Wait a minute!! What phase 2? What "safety checks"? Have Ms. Saphier ever heard about p values and NEWS-2? Or it's too much to expect from a corporate media journalist with MD degree.
Was Ms. Saphier under influence when writing her piece? I don't know. I wish she was because otherwise we must conclude that the degradation of our corporate media has gone so far that even issues of gravest significance for the nation cannot be adequately presented.
Did you do your DD on LL recently . Let me help you. On Aug 17 Cytodyn submitted its Top-line report from its phase 2 COVID-19 to the FDA and requested Emergency Use Approval.
But Ms. Saphier appears to be blissfully unaware of such a trivial event as a request for EUA. I guess she was too busy to consult a "lesser known" company's list of press releases. Instead, what a potential investor or a relative of a gravely ill Covid patient learns from her piece is that one day LL may be of use but not in the foreseeable future since it had passed only Phase 1 trial. I quote:
<<Albeit a small sample size, early Phase 1 results showed patients on Leronlimab experienced 63% less seriously adverse events than the control group, while also demonstrating reduction in viral load to zero after 14 days.>>
No comparison with the life-saving plasma therapy, right? So what is our near-term future after Phase 1? According to Ms. Saphier, we are <<currently enrolling two placebo-controlled double-blind clinical trials that have already entered Phase 3. Phase 2 results reported in July passed all safety checks.>>
Wait a minute!! What phase 2? What "safety checks"? Have Ms. Saphier ever heard about p values and NEWS-2? Or it's too much to expect from a corporate media journalist with MD degree.
Was Ms. Saphier under influence when writing her piece? I don't know. I wish she was because otherwise we must conclude that the degradation of our corporate media has gone so far that even issues of gravest significance for the nation cannot be adequately presented.
(9)
(0)CytoDyn Inc (CYDY) Stock Research Links
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
Scroll down for more posts ▼